Does the media favor IRTC or CBLL?

In the previous week, iRhythm Technologies had 1 more articles in the media than CeriBell. MarketBeat recorded 11 mentions for iRhythm Technologies and 10 mentions for CeriBell. CeriBell's average media sentiment score of 0.51 beat iRhythm Technologies' score of 0.37 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLSE or CBLL?

In the previous week, CeriBell had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 10 mentions for CeriBell and 7 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat CeriBell's score of 0.51 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CeriBell 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, TMDX or CBLL?

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.63 $190.29M $3.89 20.84 CeriBell $89.06M 10.12 -$53.41M -$1.76 N/A

Does the media favor TMDX or CBLL?

In the previous week, TransMedics Group and TransMedics Group both had 10 articles in the media. CeriBell's average media sentiment score of 0.51 beat TransMedics Group's score of 0.50 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, CBLL or ATRC?

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 10.12 -$53.41M -$1.76 N/A AtriCure $534.53M 5.07 -$11.45M $0.21 253.86

Is CBLL or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% AtriCure 1.85% 2.34% 1.77%

Does the media refer more to CBLL or ATRC?

In the previous week, CeriBell had 5 more articles in the media than AtriCure. MarketBeat recorded 10 mentions for CeriBell and 5 mentions for AtriCure. CeriBell's average media sentiment score of 0.51 beat AtriCure's score of 0.22 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BFLY or CBLL?

In the previous week, Butterfly Network had 4 more articles in the media than CeriBell. MarketBeat recorded 14 mentions for Butterfly Network and 10 mentions for CeriBell. CeriBell's average media sentiment score of 0.51 beat Butterfly Network's score of 0.43 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CeriBell (CBLL) Competitors

$23.15 -0.33 (-1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$23.18 +0.04 (+0.15%)

As of 07:30 PM Eastern

Compare

CBLL vs. IRTC, PLSE, TMDX, ATRC, and BFLY

Should you buy CeriBell stock or one of its competitors? CeriBell's main competitors and comparable companies include iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), TransMedics Group (TMDX), AtriCure (ATRC), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CeriBell compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

In the previous week, iRhythm Technologies had 1 more articles in the media than CeriBell. MarketBeat recorded 11 mentions for iRhythm Technologies and 10 mentions for CeriBell. CeriBell's average media sentiment score of 0.51 beat iRhythm Technologies' score of 0.37 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies currently has a consensus target price of $178.79, suggesting a potential upside of 70.29%. CeriBell has a consensus target price of $27.00, suggesting a potential upside of 14.99%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe iRhythm Technologies is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

iRhythm Technologies has higher revenue and earnings than CeriBell. iRhythm Technologies is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.63	-$44.55M	-$0.43	N/A
CeriBell	$89.06M	10.12	-$53.41M	-$1.76	N/A

iRhythm Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

iRhythm Technologies has a net margin of -1.69% compared to CeriBell's net margin of -64.73%. iRhythm Technologies' return on equity of 10.11% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
CeriBell	-64.73%	-44.85%	-35.69%

Summary

iRhythm Technologies beats CeriBell on 12 of the 15 factors compared between the two stocks.

How does CeriBell compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, CeriBell had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 10 mentions for CeriBell and 7 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat CeriBell's score of 0.51 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Pulse Biosciences presently has a consensus price target of $53.20, indicating a potential upside of 8.37%. CeriBell has a consensus price target of $27.00, indicating a potential upside of 14.99%. Given CeriBell's higher probable upside, analysts plainly believe CeriBell is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

CeriBell has a net margin of -64.73% compared to Pulse Biosciences' net margin of -6,755.78%. CeriBell's return on equity of -44.85% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
CeriBell	-64.73%	-44.85%	-35.69%

CeriBell has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,930.21	-$72.78M	-$1.18	N/A
CeriBell	$89.06M	10.12	-$53.41M	-$1.76	N/A

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 17.7% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pulse Biosciences and CeriBell tied by winning 8 of the 16 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

TransMedics Group has a net margin of 22.69% compared to CeriBell's net margin of -64.73%. TransMedics Group's return on equity of 15.88% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
CeriBell	-64.73%	-44.85%	-35.69%

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 17.7% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.63	$190.29M	$3.89	20.84
CeriBell	$89.06M	10.12	-$53.41M	-$1.76	N/A

In the previous week, TransMedics Group and TransMedics Group both had 10 articles in the media. CeriBell's average media sentiment score of 0.51 beat TransMedics Group's score of 0.50 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group presently has a consensus target price of $121.00, suggesting a potential upside of 49.25%. CeriBell has a consensus target price of $27.00, suggesting a potential upside of 14.99%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

TransMedics Group has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

TransMedics Group beats CeriBell on 11 of the 16 factors compared between the two stocks.

How does CeriBell compare to AtriCure?

CeriBell (NASDAQ:CBLL) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	10.12	-$53.41M	-$1.76	N/A
AtriCure	$534.53M	5.07	-$11.45M	$0.21	253.86

CeriBell presently has a consensus target price of $27.00, suggesting a potential upside of 14.99%. AtriCure has a consensus target price of $53.30, suggesting a potential downside of 0.02%. Given CeriBell's stronger consensus rating and higher probable upside, equities research analysts clearly believe CeriBell is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

99.1% of AtriCure shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
AtriCure	1.85%	2.34%	1.77%

CeriBell has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

In the previous week, CeriBell had 5 more articles in the media than AtriCure. MarketBeat recorded 10 mentions for CeriBell and 5 mentions for AtriCure. CeriBell's average media sentiment score of 0.51 beat AtriCure's score of 0.22 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AtriCure beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does CeriBell compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Butterfly Network currently has a consensus price target of $8.54, indicating a potential upside of 3.37%. CeriBell has a consensus price target of $27.00, indicating a potential upside of 14.99%. Given CeriBell's higher probable upside, analysts plainly believe CeriBell is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Comparatively, 17.7% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Butterfly Network had 4 more articles in the media than CeriBell. MarketBeat recorded 14 mentions for Butterfly Network and 10 mentions for CeriBell. CeriBell's average media sentiment score of 0.51 beat Butterfly Network's score of 0.43 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a net margin of -64.73% compared to Butterfly Network's net margin of -66.74%. Butterfly Network's return on equity of -33.99% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
CeriBell	-64.73%	-44.85%	-35.69%

CeriBell has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	22.54	-$77.06M	-$0.29	N/A
CeriBell	$89.06M	10.12	-$53.41M	-$1.76	N/A

Butterfly Network has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

Butterfly Network beats CeriBell on 9 of the 14 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$901.12M	$5.46B	$7.20B	$13.40B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-13.15	25.29	274.55	25.95
Price / Sales	9.98	69.02	575.97	86.00
Price / Cash	N/A	32.10	76.82	53.72
Price / Book	5.53	5.88	10.81	6.27
Net Income	-$53.41M	$146.72M	$3.50B	$382.01M
7 Day Performance	-1.95%	-0.66%	-2.02%	-1.35%
1 Month Performance	-4.77%	-4.58%	-7.53%	-5.60%
1 Year Performance	89.13%	1.17%	3.32%	-1.54%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	2.9351 of 5 stars	$23.15 -1.4%	$27.00 +16.6%	+99.0%	$901.12M	$89.06M	N/A	300
IRTC iRhythm Technologies	3.4243 of 5 stars	$107.22 -1.7%	$178.79 +66.7%	-40.9%	$3.53B	$825.34M	N/A	2,400	News Coverage Analyst Forecast
PLSE Pulse Biosciences	2.5078 of 5 stars	$49.25 -2.5%	$53.20 +8.0%	+147.1%	$3.49B	$350K	N/A	116	News Coverage Analyst Forecast
TMDX TransMedics Group	4.4203 of 5 stars	$80.21 -3.4%	$121.10 +51.0%	-29.6%	$2.77B	$668.47M	20.63	898	News Coverage Analyst Forecast
ATRC AtriCure	2.1155 of 5 stars	$53.56 -5.0%	$53.30 -0.5%	+56.2%	$2.72B	$534.53M	254.98	1,350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. IRTC, PLSE, TMDX, ATRC, and BFLY

How does CeriBell compare to iRhythm Technologies?

Summary

How does CeriBell compare to Pulse Biosciences?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to AtriCure?

Summary

How does CeriBell compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. IRTC, PLSE, TMDX, ATRC, and BFLY

How does CeriBell compare to iRhythm Technologies?

Does the media favor IRTC or CBLL?

Do analysts prefer IRTC or CBLL?

Which has higher earnings & valuation, IRTC or CBLL?

Which has more volatility & risk, IRTC or CBLL?

Is IRTC or CBLL more profitable?

Summary

How does CeriBell compare to Pulse Biosciences?

Does the media favor PLSE or CBLL?

Which has more volatility & risk, PLSE or CBLL?

Do analysts prefer PLSE or CBLL?

Is PLSE or CBLL more profitable?

Which has stronger valuation and earnings, PLSE or CBLL?

Do insiders and institutionals believe in PLSE or CBLL?

Summary

How does CeriBell compare to TransMedics Group?

Is TMDX or CBLL more profitable?

Do insiders and institutionals hold more shares of TMDX or CBLL?

Which has higher earnings & valuation, TMDX or CBLL?

Does the media favor TMDX or CBLL?

Do analysts rate TMDX or CBLL?

Which has more volatility & risk, TMDX or CBLL?

Summary

How does CeriBell compare to AtriCure?

Which has better valuation and earnings, CBLL or ATRC?

Do analysts rate CBLL or ATRC?

Do institutionals and insiders hold more shares of CBLL or ATRC?

Is CBLL or ATRC more profitable?

Which has more risk & volatility, CBLL or ATRC?

Does the media refer more to CBLL or ATRC?

Summary

How does CeriBell compare to Butterfly Network?

Do analysts rate BFLY or CBLL?

Do institutionals & insiders have more ownership in BFLY or CBLL?

Does the media favor BFLY or CBLL?

Is BFLY or CBLL more profitable?

Which has better earnings and valuation, BFLY or CBLL?

Which has more risk and volatility, BFLY or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools